US2019240287A1PendingUtilityA1

Inhibitor of rna polymerase ii

34
Assignee: LINNANE PHARMA ABPriority: Oct 17, 2016Filed: Oct 16, 2017Published: Aug 8, 2019
Est. expiryOct 17, 2036(~10.2 yrs left)· nominal 20-yr term from priority
Inventors:Catharina SvanborgNina FilenkoInes Ambite
A61P 13/02A61P 13/00A61K 38/164G01N 2333/91255A61K 38/443A61K 35/74G01N 33/573Y02A50/30
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides expressed by a gene selected from lldD, lldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or NplD proteins. These inhibitors are useful in therapies, to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti-infection agents.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising an inhibitor of RNA polymerase II and a pharmaceutically acceptable carrier, wherein said inhibitor targets a protein selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. 
     
     
         2 . The pharmaceutical composition according to  claim 1  wherein the inhibitor is a polypeptide expressed by a gene selected from lldD, lldR, nlpD or rfaH of a bacterial species, or a variant of said protein. 
     
     
         3 . The pharmaceutical composition according to  claim 2  wherein the bacteria is a commensal bacteria or an asymptomatic carrier. 
     
     
         4 . The pharmaceutical composition according to  claim 3  wherein the bacteria is asymptomatic bacteriuria (ABU). 
     
     
         5 . The pharmaceutical composition according to  claim 2  wherein the bacteria is an  E. coli  strain. 
     
     
         6 . The pharmaceutical composition according to  claim 5  wherein the bacteria are  E. coli  83972. 
     
     
         7 . The pharmaceutical composition according to  claim 1  wherein the inhibitor is a Sigma S protein or a variant thereof or an active fragment of either of these. 
     
     
         8 . The pharmaceutical composition according to  claim 7  wherein the Sigma S protein is e# SEQ ID NO 1 or SEQ ID NO 2 or SEQ ID NO 3. 
     
     
         9 . The pharmaceutical composition according to  claim 1  wherein the inhibitor is a bacterial NplD protein, or a variant thereof, or an active fragment of either of these. 
     
     
         10 . The pharmaceutical composition according to  claim 9  wherein the bacterial NplD protein is SEQ ID NO 4. 
     
     
         11 . The pharmaceutical composition according to  claim 2  wherein the inhibitor is secreted by the bacteria. 
     
     
         12 . The pharmaceutical composition according to  claim 9  wherein the inhibitor is of less than 3 kDa in molecular weight. 
     
     
         13 . The pharmaceutical composition according to  claim 2  wherein the inhibitor is synthetic. 
     
     
         14 . (canceled) 
     
     
         15 . A method for preparing an inhibitor of RNA polymerase II that is expressed by a bacterial species which comprises culturing suitable bacteria in a culture medium, and isolating a factor having RNA polymerase II inhibitor activity from the supernatant. 
     
     
         16 . (canceled) 
     
     
         17 . A method for providing immunosuppression, anti-inflammatory or anti-infection therapy to a patient in need therefore, the method comprising administering to the patient an effective amount of an inhibitor of RNA polymerase II. 
     
     
         18 - 27 . (canceled) 
     
     
         28 . The method of  claim 17 , wherein the inhibitor is a polypeptide expressed by a gene selected from lldD, lldR, nlpD or rfaH of a bacterial species, or a variant of said protein. 
     
     
         29 . The method of  claim 17 , wherein the inhibitor is a bacterial NplD protein, or variant thereof, or active fragment of either of these. 
     
     
         30 . The method of  claim 29 , wherein the bacterial NplD protein is SEQ ID NO 4. 
     
     
         31 . The method of  claim 17 , wherein the inhibitor is a Sigma S protein, or a variant thereof, or an active fragment of either of these. 
     
     
         32 . The method of  claim 31 , wherein the Sigma S protein is SEQ ID NO 1 or SEQ ID NO 2 or SEQ ID NO 3.

Join the waitlist — get patent alerts

Track US2019240287A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.